Evaluation of Clinical Effectiveness of Choline Alphoscerate for Older Adults With Major Depression and Subjective Memory Complaints: a Double-blinded, Placebo-controlled, Randomization, Multicenter Investigator-initiated Trial

To evaluate the efficacy of choline alphoscerate on improving symptoms related to depression, anxiety, and subjective memory complaints compared to placebo in patients with Major Depressive Disorder(MDD) accompanied with subjective cognitive decline, who are over the age of 60.

开始日期2022-03-01

申办/合作机构

Samsung Medical Center

NCT05383183

/ Recruiting临床4期

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Patients With Mild to Moderate Alzheimer's Disease

The purpose of this study is to determine whether combination of donepezil, a cholinesterase inhibitor, with choline alfoscerate has a more favourable clinical profile than monotherapy with donepezil alone.

开始日期2022-01-20

申办/合作机构

Daewoong Bio, Inc.

100 项与甘磷酸胆碱相关的临床结果

登录后查看更多信息

100 项与甘磷酸胆碱相关的转化医学

登录后查看更多信息

100 项与甘磷酸胆碱相关的专利（医药）

登录后查看更多信息

2,555

项与甘磷酸胆碱相关的文献（医药）

2025-06-01·Case Studies in Chemical and Environmental Engineering

Untargeted metabolomic LC-HRMS combined with chemometric reveal metabolites change from sorghum flakes affected by food processing

作者: Anggraeni, Ayu Septi ; Suratno ; Noviana, Ika Mulawati Purwanti ; Utami, Indrawati Dian ; Nurfahmi, Laely ; Khasanah, Yuniar ; Alam, Lucky Prabowo Miftachul ; Windarsih, Anjar

A non-targeted UHPLC-HRMS metabolomics approach combined with chemometric anal. was employed to assess the change in metabolite profiles of sorghum flakes based on food processing techniques.The result showed that fatty acids were the most abundant metabolites, followed by lipids, amino acids, alkaloids, amines, and polyphenols, representing key metabolic markers influenced by food processing in sorghum flakes.Specific metabolites, including 15S-Hydroxyeicosatrienoic acid (15S-HETrE), terminaline, vitamin E acetate, furan fatty acid F6, all-trans-retinal, and fingolimod, exhibited increased concentrations during oven processing compared to raw sorghum, likely due to their thermal stability.This study provides valuable insights into effect of food processing effect on metabolites profiles.

2025-01-01·PHYSIOLOGIA PLANTARUM

The spatiotemporal changes of metabolites in Pinellia ternata at different development stages by MALDI‐MSI

Article

作者: Liu, Haitao ; Zhang, Xiangyu ; Liu, Ziyi ; Wang, Jialu ; Li, Xiwen ; Pei, Yifei ; Feng, Xue ; Chen, Jialei

Abstract:

Pinellia ternata is an herb species in the Pinellia genus with significant economic value due to its medicinal properties. Understanding the accumulation and spatial distribution characteristics of metabolites during the development of the medicinal part, the rhizome of P. ternata (PR), provides a basis for targeted metabolic regulation and quality evaluation. In this study, we used matrix‐assisted laser desorption/ionization mass spectrometry imaging (MALDI) and MS/MS to analyse metabolites at 5 representative stages (S1 to S5) of rhizome development in cross and longitudinal sections of the rhizome. A total of 168 metabolites were detected, with 13 being metabolites previously reported in PR. Additionally, Venn analysis revealed 12 bioactive differential metabolites during the growth process. Their spatial distribution and composition were analyzed, showing that alkaloids and amino acids were significantly distributed throughout the entire region and had higher relative contents compared to other metabolites. Flavonoids were more distributed in the outer regions of PR, potentially playing a greater role in combating biotic or abiotic stresses. Specifically, in cross‐sections, arginine, nicotinamide, and 2‐pentylpyridine showed a clear trend of accumulation from the outer to the inner from S1 to S5, while trigonelline, adenosine, cytidine, 3,4‐dihydroxycinnamyl alcohol, raffinose, choline alfoscerate, liquiritin, and apii exhibited the opposite trend. For longitudinal sections, trigonelline, 2‐pentylpyridine, choline alfoscerate and baicalein showed a trend of accumulation from the area of bud end to the far region during S1 to S5, while arginine showed opposite distribution trends. These findings deepen our understanding of the metabolic processes involved in the development of PR and have potential implications for variety improvement and quality control.

2025-01-01·CLINICA CHIMICA ACTA

Intra- and inter-day variations in oral metabolites from mouth-rinsed water determined using capillary electrophoresis–mass spectrometry metabolomics

Article

作者: Hirayama, Akiyoshi ; Ichiba, Yuko ; Fujii, Narumi ; Sugimoto, Masahiro ; Maruyama, Yuki ; Yamada, Kaoru ; Kakizawa, Yasushi ; Kawamata, Ryosuke

BACKGROUND AND AIMS:

Collecting clinical samples without inconveniencing participants is desirable. The profile of metabolites in mouth-rinsed water is similar to that in saliva. However, the intra- and inter-day variations in unstimulated or stimulated saliva metabolites from mouth-rinsed water have yet to be clarified. Thus, we aimed to fill this research gap using capillary electrophoresis-mass spectrometry metabolomics.

MATERIALS AND METHODS:

We collected mouth-rinsed water from 15 healthy participants at 9:00, 11:30, 14:00, and 16:30 daily for 3 days. In total, 509 metabolite concentrations from 180 samples were obtained using capillary electrophoresis time-of-flight mass spectrometry. Variations in each metabolite were evaluated using the Wilcoxon signed-rank test to determine at which time/day significant differences occurred after removing metabolites without significant changes using the Friedman test.

RESULTS:

Of 167 frequently detected metabolites, 100 exhibited intra-day variations, and none exhibited inter-day variations. Intra-day variations were classified into four patterns, and the intra-day variation in each metabolite was assessed. The variations may reflect elapsed time after meals, oral cleaning, or circadian rhythms.

CONCLUSION:

This study could serve as a reference for improving the design of future clinical trials and the accuracy of metabolome analysis of mouth-rinsed water samples collected at different dates and times.

项与甘磷酸胆碱相关的新闻（医药）

2022-12-20

·Business Wire

World Alzheimer's Disease Therapeutics Analysis Report 2022: 101 Active Drugs - Market Insight, Epidemiology and Pipeline Assessment by Molecule Type, Route of Administration, Pipeline Phase - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Alzheimer's Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)" report has been added to ResearchAndMarkets.com's offering. Alzheimer's disease Therapeutics Pipeline Analysis has 101 active drugs undergoing several stages of clinical trials. The Alzheimer's disease Therapeutics Pipeline is driven by an increasing gap of unmet need of effective therapeutics that can cure Alzheimer's disease. Additionally, life expectancy has increased due to various healthcare reforms in major economies such as the U.S., Japan, and China. This has resulted in a large geriatric population which is the age group most affected by the disease. Alzheimer's prevalence is rising rapidly and despite decades of research, the disease remains incurable. The majority of therapeutics target symptom reduction and slowing the progression of the disease. The Food and Drug Administration (FDA) approved aducanumab (Aduhelm) for the treatment of certain cases of Alzheimer's disease in June 2021 and this is the first drug approved for Alzheimer's disease in decades. Eisai, Biogen, Hoffmann-La Roche, AZTherapies, Cerecin, Neurotrope, AC Immune, Cassava Sciences, AB Science, Anavex Life Sciences, Athira Pharma, Denali Therapeutics Inc., and other notable companies are developing therapeutic candidates to improve the Alzheimer's Diagnosis and treatment scenario. Scope of the Report The report analyses the Alzheimer's Disease Therapeutics in Pipeline by Molecule Type (Small Molecules, Monoclonal Antibody, Vaccine, DNA/RNA Based, Natural products, Gene Therapy, Cell Therapy, Others). The report analyses the Alzheimer's disease Therapeutics by Route of Administration (Oral, Intravenous, Intramuscular, Subcutaneous, Intrathecal, Intranasal, Other). The report analyses the Alzheimer's disease Therapeutics by Pipeline Phase (Phase I, Phase I/II, Phase II, Phase II/III, Phase III, Phase IV, Preclinical). The report analyses the Pain Management Drugs Market by Availability (Over the Counter (OTC), Prescription). The Alzheimer's Disease Therapeutics Pipeline Analysis has been analysed By Region (Americas, Europe, Asia Pacific, and MEA). The Global Pain Management Drugs Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA). The key insights of the report have been presented through the leading company shares. Also, the major, trends, drivers and challenges as well as Unmet Needs of the industry has been analysed in the report. The companies analysed in the report include Eli-Lily & Co , Elsal Co., Ltd., BioVie, Johnson and Johnson, Otsuka Pharmaceutical Co., Ltd. H. Lundbeck A/S, Novartis, Cognition Therapeutics, Merck Sharp & Dohme LLC, Biogen. Key Target Audience Alzheimer's Disease Therapeutics Companies End Users (Hospitals and clinics) Research and Development (R&D) Organizations Government Bodies & Regulating Authorities Investment Banks and Equity Firms Key Topics Covered: 1. Introduction 1.1 Alzheimer's Disease Therapeutics Overview 1.2 Scope of Research 2. Executive Summary 2.1 Market Dashboard 2.2 Regional Insights 2.3 Market Ecosystem Factors 3. Research Methodology 3.1 Data Collection Process 3.2 Market Size Calculation-Top-to-Bottom 4. Macro Economic Indicator Outlook 4.1 Global, Region wise GDP Growth 4.2 Global Medical Spending 4.3 Current Healthcare Expenditure 4.4 Pharmaceutical Spending/capita 5. Competitive Positioning 5.1 Companies' Product Positioning 5.2 Competitive positioning 5.2.1 Eli-Lily & Co 5.2.2 Elsal Co., Ltd. 5.2.3 BioVie 5.2.4 Johnson & Johnson 5.2.5 Otsuka Pharmaceutical Co., Ltd. 5.2.6 H. Lundbeck A/S 5.2.7 Novartis 5.2.8 Cognition Therapeutics 5.2.9 Merck Sharp & Dohme LLC 5.2.10 Biogen 6. Alzheimer's disease background 6.1 AD Fact Sheet 6.2 Epidemiology 6.3 Causes and Risk Factors 6.4 Diagnosis and Assessment 6.5 Unmet Needs 7. Therapeutics in Pipeline 7.1 Pipeline Scenario 7.2 Alzheimer's Therapeutics Comparative Review 8. Pipeline Analysis 9. Phase I therapeutics Overview 9.1 LY3372993 9.1.1 Drug Description 9.1.2 Outcomes 9.2 Lu AF87908 9.3 anle138b 9.4 ASN51 9.5 CMS121 9.6 IBC-Ab002 9.7 LX1001 9.8 MK-2214 9.9 MK-8189 9.10 ACU193 9.11 NIO752 9.12 ALN-APP 9.13 TB006 9.14 SNK01 9.15 Pepinemab 9.16 GB-5001 9.17 AC-1202 9.18 SHR-1707 9.19 BEY2153 9.20 JNJ-40346527 9.21 APNmAb005 9.22 NPT 2042 9.23 ALZ-101 10. Phase I/II therapeutics Overview 10.1 Posiphen 10.1.1 Drug Description 10.1.2 Outcomes 10.1.3 Collaborators 10.2 PrimeProT/ PrimeMSKT 10.3 TB006 10.4 RO7126209 10.5 DNL593 10.6 BIIB080 10.7 E2814 10.8 Tdap 10.9 ACI-35.030/ JACI-35.054 10.10 ACI-24.060 10.11 IVL3003 11. Phase II therapeutics Overview 11.1 Lecanemab 11.1.1 Drug Description 11.1.2 Outcomes 11.1.3 Collaborators 11.2 Lomecel-B 11.3 AL002 11.4 AL001 11.5 CT1812 (Elaya) 11.6 APH-1105 11.7 ATH-1017 11.8 T-817MA 11.9 Montelukast buccal film 11.10 ABBV-916 11.11 Bepranemab 11.12 TB006 11.13 LY3372689 11.14 MW150 11.15 EX039 11.16 JNJ-42847922 11.17 REM0046127 11.18 Bryostatin 1 11.19 NanoLithium NP03 11.20 AstroStem 11.21 Gantenerumab 11.22 Semorinemab 11.23 Obicetrapib 11.24 ALZ-801 11.25 CY6463 11.26 Crenezumab 11.27 T3D-959 11.28 PMZ-1620 11.29 GV1001 11.30 ACZ885 11.31 PQ912 11.32 APH-1105 11.33 SLS-005 11.34 Flos gossypii flavonoids 11.35 Human Mesenchymal Stem cells (MSCs) 11.36 JNJ-63733657 11.37 IGC-AD1 11.38 TW001 11.39 ABvac40 12. Phase II/III therapeutics Overview 12.1 Tricaprilin 12.1.1 Drug Description 12.1.2 Outcomes 12.2 ANAVEX2-73 12.3 Piromelatine 12.4 AGB101 13. Phase III therapeutics Overview 13.1 Simufilam 13.1.1 Drug Description 13.1.2 Outcomes 13.1.3 Collaborators 13.2 ATH-1017 13.3 Lecanemab 13.4 Nilotinib BE 13.5 Brexpiprazole 13.6 Masitinib 13.7 Remternetug 13.8 Donanemab 13.9 NE3107 13.10 Gantenerumab 13.11 GV-971 13.12 Aducanumab 13.13 TRx0237 13.14 Semagludtide 13.15 BPDO-1603 13.16 AR1001 13.17 KarXT 13.18 AXS-05 14. Phase IV therapeutics Overview 14.1 Choline Alfoscerate 14.1.1 Drug Description 14.1.2 Outcomes 14.2 Ebicomb 14.3 Rivastigmine 14.4 GV-971 15. Preclinical Phase therapeutics Overview 15.1 PMN310 15.1.1 Drug Description 15.1.2 Outcomes 15.1.3 Collaborators 15.2 PRX123 16. Pipeline analysis, By molecule type 16.1 Alzheimer's Therapeutics Comparative Review, by Molecule type 17. Pipeline analysis, By Route of Administration 17.1 Alzheimer's Therapeutics Comparative Review, By Route of Administration For more information about this report visit https://www.researchandmarkets.com/r/wcw7f7

上市批准临床2期临床1期

100 项与甘磷酸胆碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07349	甘磷酸胆碱	N07AX02	DB04660

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
认知障碍	意大利	Italfarmaco SpA	1996-04-03
阿尔茨海默症	-	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


P27.06.B (EANO2024)	N/A	胶质母细胞瘤 isocitrate dehydrongenase (IDH)-wild-type	187	Choline alphoscerate (GPC) ≥12 months	壓積鏇鏇鹽構蓋選製鑰(廠醖範艱顧選鑰積選願) = 餘壓築構襯憲繭願壓獵餘願襯蓋糧鬱餘願襯簾 (鏇鹹醖積鬱簾鬱壓齋觸 )	积极	2024-10-17
				Choline Alphoscerate (Control group (<12 months))	壓積鏇鏇鹽構蓋選製鑰(廠醖範艱顧選鑰積選願) = 壓糧觸願蓋窪夢蓋衊襯餘願襯蓋糧鬱餘願襯簾 (鏇鹹醖積鬱簾鬱壓齋觸 )
SNO2023	N/A	胶质母细胞瘤 isocitrate dehydrongenase (IDH)-wild-type	187	Choline alphoscerate (GPC) ≥12 months	顧壓選積顧醖膚築製衊(願構鏇簾窪鹽繭艱製鏇) = 鹽醖淵遞觸齋餘蓋醖構廠築鏇壓廠積淵衊糧簾 (憲鹹獵簾糧顧憲鹽鹽夢 )	积极	2023-11-10
				Choline Alphoscerate (Control group (<12 months))	顧壓選積顧醖膚築製衊(願構鏇簾窪鹽繭艱製鏇) = 醖醖艱製鬱蓋鹽廠願觸廠築鏇壓廠積淵衊糧簾 (憲鹹獵簾糧顧憲鹽鹽夢 )
UEGW2014	N/A	肝性脑病	-	Choline alphoscerate (intervention group)	繭齋餘顧壓齋獵齋鹹窪(襯艱簾餘築夢壓廠壓襯) = 鑰壓鹽積襯齋窪鬱醖鏇選製鹹觸獵蓋膚衊積願 (襯鑰構廠壓簾築餘鹹廠 ) 更多	-	2014-10-01
				Standard treatment (control group)	繭齋餘顧壓齋獵齋鹹窪(襯艱簾餘築夢壓廠壓襯) = 憲鏇艱廠鏇願壓蓋獵築選製鹹觸獵蓋膚衊積願 (襯鑰構廠壓簾築餘鹹廠 ) 更多